SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is trending after announcing stellar earnings and strong forward guidance, primarily driven by its AI data center business; however, the stock's mixed after-hours reaction has sparked widespread community debate on whether the AI growth narrative is fully priced in or if market makers are actively suppressing its price movement.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Trade Desk is trending after a significant stock decline driven by softer-than-expected Q1 revenue and EBITDA guidance, despite an EPS beat for Q4. This has sparked intense debate among the community, with some investors viewing the multi-year low as a prime 'buy the dip' opportunity given strong fundamentals and buyback programs, while others express deep concern over its long-term competitive position against rivals like $ZETA and management's strategy.

Salesforce, Inc. engages in the design and development of cloud-based enterprise software for customer relationship management. Its solutions include sales force automation, customer service and support, marketing automation, digital commerce, community management, collaboration, industry-specific solutions, and salesforce platform. The firm also provides guidance, support, training, and advisory services. The company was founded by Marc Russell Benioff and Parker Harris in 1999 and is headquartered in San Francisco, CA.

Salesforce Inc

Salesforce is trending after its Q4 earnings report, which delivered strong beats on revenue and EPS, a dividend increase, and an impressive $50 billion share buyback program. Despite these positives, mixed guidance and persistent AI disruption fears for the software sector caused an initial market sell-off, leading to a contentious debate among investors.

Larimar Therapeutics, Inc. Is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics mitochondrial disorders and Friedreich's ataxia. The company was founded in 2005 and is headquartered in Bala Cynwyd, PA.

Larimar Therapeutics Inc

Larimar Therapeutics is seeing intense trading activity after receiving FDA Breakthrough Therapy Designation for its Friedreich's ataxia drug, nomlabofusp, leading to strong investor optimism for accelerated approval and significant upside. However, an upsized public offering and inherent biotech volatility are fueling active debate among the community about its immediate price trajectory.

C3.ai, Inc. engages in the provision of enterprise artificial intelligence software for digital transformation. It delivers the C3 AI suite for developing, deploying, and operating large-scale AI, predictive analytics, and Internet of Things applications in addition to a portfolio of turn-key AI applications. It operates through the following geographical segments: North America, Europe, The Middle East, and Africa, Asia Pacific, and Rest of World. The company was founded by Thomas M. Siebel, Patricia A. House and Stephen Maurice Ward, Jr. on January 8, 2009 and is headquartered in Redwood City, CA.

C3.ai Inc - Ordinary Shares - Class A

C3.ai Inc

C3.ai is trending amid abysmal financial results and deeply negative guidance, contrasted by circulating rumors of a potential merger with Automation Anywhere. The community is sharply divided, with many dismissing the company as "garbage" despite its prime ticker, while others speculate on a short squeeze or a turnaround from merger news.

JD.com, Inc. is a technology-driven E-commerce company, which engages in the sale of electronics products and general merchandise products, including audio, video products, and books. It operates in the following segments: JD Retail, JD Logistics, and New Businesses. The JD Retail segment offers online retail, online marketplace, and marketing services. The JD Logistics segment includes internal and external logistics businesses. The New Businesses segment is composed of JD Property, Jingxi, overseas businesses and technology initiatives. The company was founded on June 18, 1998, by Qiang Dong Liu and is headquartered in Beijing, China.

JD.com Inc - ADR

JD.com is a major talking point as investors express extreme frustration over its persistent underperformance and lack of stock price appreciation, even as its Chinese tech peers rally. The community is keenly focused on upcoming earnings and widely critical of management's perceived inaction on share buybacks, despite the company's strong fundamentals and substantial cash reserves.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending amidst mixed Q4 earnings, the announced retirement of CEO Doug Ingram, and the commercial launch of Elevidys in Japan. The community is highly focused on potential buyout opportunities and the stock's perceived undervaluation given its nearly $2 billion in annual revenue and robust pipeline, with many frustrated by persistent short-seller activity.

Snowflake, Inc. engages in the provision of cloud data warehousing software. The firm offers Data Cloud, an ecosystem where Snowflake customers, partners, data providers, and data consumers can break down data silos and derive value from data. Its platform supports a range of use cases including data warehousing, data lakes, data engineering, data science, data application development, and data sharing. The cloud-native architecture consists of layers across storage, compute, and cloud services. The storage layer ingests structured and semi-structured data to create a unified data record. The compute layer provides dedicated resources to enable users to access common data sets for many use cases without latency. The cloud services layer optimizes each use case's performance requirements with no administration. The company was founded by Marcin Zukowski, Thierry Cruanes, and Benoit Dageville on July 23, 2012 and is headquartered in Bozeman, MT.

Snowflake Inc

Snowflake is trending after reporting Q4 earnings that surpassed estimates, but its conservative guidance for future product revenue and a lack of clarity on AI monetization disappointed investors. This fuels community discussion about AI's impact on consumption models and contributes to a broader sell-off in the software sector.

Infinite Money Glitch ($IMG) is revolutionizing DeFi on Solana by leveraging the Token2022 program's advanced tax extension capabilities to create a truly innovative reward system for token holders.  At its core, $IMG implements a seamless 5% tax on all transactions - whether buying, selling, or transferring tokens. This tax is automatically collected and distributed to holders in SOL, creating a sustainable passive income stream for the community. 4.5% of the tax gets sent to holders, while .5% gets sent to an Infrastructure wallet to help with development, marketing and general infrastructure.  What sets $IMG apart is its implementation of Solana's Token2022 program, enabling automated and efficient reward distribution without relying on external smart contracts.

Infinite Money Glitch

IMG CRYPTO is trending as its dedicated community celebrates a significant milestone, highlighting the "Infinite Money Glitch" model that provides passive Solana rewards to holders based on transaction volume. Despite community discussions around past volatility and allegations of it being a "scam," supporters emphasize its resilience, battle-tested nature, and anticipated new features like enhanced liquidity pool rewards and a live audit platform.

Enovix Corp. engages in the design and development of silicon-anode lithium-ion batteries. The firm's proprietary 3D cell architecture increases energy density and maintains a high cycle life. It is also developing its 3D cell technology and production process for the electric vehicle and energy storage markets to help enable utilization of renewable energy. The company was founded by Mr. Harrold Jones Rust, III, Ashok Lahiri, and Murali Ramasubramanian in November 2006 and is headquartered in Fremont, CA.

Enovix Corporation

Enovix Corp

Enovix is trending following a mixed earnings report that beat revenue expectations but offered weaker Q1 guidance, sparking debate. While the first commercial purchase order for smart eyewear batteries is seen by some as a crucial validation of their technology, the community is actively discussing persistent delays in smartphone qualification and manufacturing yield challenges, leading to significant investor frustration and a divided outlook.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Maze Therapeutics, Inc. (NASDAQ:MAZE) Receives Consensus Rating of "Buy" from Analysts

Shares of Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) have been assigned a consensus rating of "Buy" from the eleven analysts that are presently covering the firm, MarketBeat.com reports...

Maze Therapeutics Chief Medical Officer Sells 15K Shares As Company's Stock Continues to Surge

Key PointsChief Medical Officer Harold Bernstein exercised 15,000 shares, which were sold immediately for a total transaction value of approximately $690,300 on Feb. 2, 2026...

Maze Therapeutics Highlights Upcoming MZE829 Kidney Data, Maps Phase 2 Plans for MZE782 at Summit

Maze Therapeutics (NASDAQ:MAZE) is advancing a genetics-driven approach to drug development, using human genetic analyses to identify gene variants linked to disease and then applying those insights...

Maze Therapeutics (NASDAQ:MAZE) Lowered to "Sell" Rating by Wall Street Zen

Wall Street Zen downgraded shares of Maze Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday...

Maze Therapeutics (NASDAQ:MAZE) CMO Harold Bernstein Sells 15,000 Shares

Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) CMO Harold Bernstein sold 15,000 shares of the stock in a transaction on Monday, February 2nd. The stock was sold at an average price of...

Maze Therapeutics (NASDAQ:MAZE) Sets New 12-Month High - Should You Buy?

Maze Therapeutics (NASDAQ:MAZE) Hits New 12-Month High - Time to Buy...

Maze Therapeutics (NASDAQ:MAZE) Insider Sells $332,025.00 in Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) insider Atul Dandekar sold 7,500 shares of Maze Therapeutics stock in a transaction dated Thursday, January 29th. The stock was sold at an...

Strs Ohio Decreases Stake in Maze Therapeutics, Inc. $MAZE

Strs Ohio cut its position in Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report) by 61.8% during the third quarter, according to the company in its most recent 13F filing with the Securities and...

Maze Therapeutics SVP Sells 5,000 Shares Amid Historic First Year for the Company's Stock

Key PointsAmy Bachrodt exercised 5,000 shares and immediately sold them for approximately $227,612 on Jan. 22, 2026...

Insider Selling: Maze Therapeutics (NASDAQ:MAZE) SVP Sells 5,000 Shares of Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) SVP Amy Bachrodt sold 5,000 shares of the company's stock in a transaction that occurred on Thursday, January 22nd. The stock was sold at an...

Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM diseases. Its pipeline includes the Compass platform, which allows it to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process to refer a variant functionalization. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman on August 29, 2017 and is headquartered in San Francisco, CA.

MAZE
Maze Therapeutics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MAZE News

MAZEMaze Therapeutics Inc.